Xenon Pharmaceuticals (XENE)
(Real Time Quote from BATS)
$39.87 USD
-0.28 (-0.70%)
Updated Sep 23, 2024 02:44 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Xenon Pharmaceuticals (XENE) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$58.17 | $65.00 | $49.00 | 44.88% |
Price Target
Based on short-term price targets offered by 15 analysts, the average price target for Xenon Pharmaceuticals comes to $58.17. The forecasts range from a low of $49.00 to a high of $65.00. The average price target represents an increase of 44.88% from the last closing price of $40.15.
Analyst Price Targets (15)
Broker Rating
Xenon Pharmaceuticals currently has an average brokerage recommendation (ABR) of 1.12 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 17 brokerage firms. The current ABR compares to an ABR of 1.12 a month ago based on 17 recommendations.
Of the 17 recommendations deriving the current ABR, 15 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 88.24% and 11.76% of all recommendations. A month ago, Strong Buy made up 88.24%, while Buy represented 11.76%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 15 | 15 | 15 | 15 | 15 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.12 | 1.12 | 1.12 | 1.12 | 1.12 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/30/2024 | William Blair | Myles R Minter | Not Available | Strong Buy |
8/28/2024 | Robert W. Baird & Co. | Brian P Skorney | Strong Buy | Strong Buy |
8/12/2024 | Needham & Company | Serge Belanger | Moderate Buy | Moderate Buy |
8/9/2024 | Wedbush Securities | Laura Chico | Strong Buy | Strong Buy |
8/9/2024 | Guggenheim Securities | Yatin Suneja | Strong Buy | Strong Buy |
8/9/2024 | Cantor Fitzgerald & Co | Josh Schimmer | Strong Buy | Strong Buy |
8/9/2024 | Wells Fargo Securities | Mohit Bansal | Strong Buy | Strong Buy |
7/9/2024 | SVB Securities | Marc Goodman | Strong Buy | Strong Buy |
6/28/2024 | Goldman Sachs | Paul K Choi | Strong Buy | Strong Buy |
6/18/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
5/10/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/10/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Joseph Thome | Strong Buy | Strong Buy |
3/15/2024 | Bloom Burton & Company | David Martin | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.12 |
ABR (Last week) | 1.12 |
# of Recs in ABR | 17 |
Average Target Price | $58.17 |
LT Growth Rate | 3.50% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 79 of 253 |
Current Quarter EPS Est: | -0.85 |
XENE FAQs
Xenon Pharmaceuticals Inc. (XENE) currently has an average brokerage recommendation (ABR) of 1.12 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 17 brokerage firms.
The average price target for Xenon Pharmaceuticals Inc. (XENE) is $58.17. The current on short-term price targets is based on 10 reports.
The forecasts for Xenon Pharmaceuticals Inc. (XENE) range from a low of $49 to a high of $65. The average price target represents a increase of $44.88 from the last closing price of $40.15.
The current UPSIDE for Xenon Pharmaceuticals Inc. (XENE) is 44.88%
Based on short-term price targets offered by 15 analysts, the average price target for Xenon Pharmaceuticals comes to $58.17. The forecasts range from a low of $49.00 to a high of $65.00. The average price target represents an increase of 44.88% from the last closing price of $40.15.